Substituted homo-isoflavonoids were synthesized in order to study their in vitro anti-picornavirus activity. The maximum non-toxic concentration of the compounds for susceptible cells (Hela) was determined, and the ability of non-cytotoxic concentrations to interfere with plaque formation by human rhinovirus (HRV) 1Band 14 and poliovirus (PV) 2 was examined. All the tested compounds were weakly effective against PV-2, while they exhibited a variable degree of activity against HRV-1 Band -14 infection. Serotype 1B was much more sensitive than 14 to the action of the compounds, and the presence of one or more chlorine atoms increased the antiviral effect in all homoisoflavonoids tested, confirming the positive influence of this substituent on activity.
Introduction
Homo-isoflavonoids constitute a small class of natural products whose first member was isolated in 1967 from bulbs of Eucomis bicolour Bak (Bohler & Tamm, 1967) . Subsequently, a number of homo-isoflavonoids were found to be prevalent in several genera of Lillaceae and Caesalpinioideae (Leguminosae) (Namikoshi et al., 1987) . These compounds belong to three structural types: (E)and (Z)-3-benzylidenechroman-4-ones (1), 3-benzyl-4chromones (2) and 3-benzylchroman-4-ones (3) (Fig. 1 ). Although exclusively (Z)-3-benzylidenechroman-4-ones occur in living plants, (Z) ,(E)-isomerization takes place very readily and therefore only the (E)-isomers are usually detected. During the last few decades, homo-isoflavonoids have been studied for their chemical and biochemical synthesis and medicinal application. Natural and synthetic homo-isoflavonoids have been recognized to possessvarious biological properties such as anti-fungal (Ravise & Kirkiacharian, 1978; Al Nakib et al., 1990) , anti-mutagenic (Wall et al., 1989) , anti-inflammatory, analgesic (Darmanaden et al., 1984; Della Loggia et al., 1989) , angioprotective, anti-allergic, anti-histaminic (Kirkiacharian et al., 1989) and phosphodiesterase inhibitor (Amschler et al., 1996) activities. However, no data are available on the antiviral activity of this group of flavonoids, although their structure is closely related to known anti-picornavirus compounds such as chalcone Ro 09-0410 and flavone Ro 09-0179 (De Meyer et al, 1991; Ishitsuka et al., 1982) . (Fig. 2) .
Therefore, because of their structural similarity to the flavanoids previously studied by us (Burali et al., 1987; Conti et al., 1988 Conti et al., , 1990a Conti et al., , b, 1992 Desideri et al., 1990 Desideri et al., , 1992 Desideri et al., ,1995 Quaglia et al., 1991 Quaglia et al., , 1992 Quaglia et al., , 1993 Superti et al., 1989; Genovese et al., 1995) , we became interested in synthesizing a series of substituted horno-isoflavones (1, 2, 3a-g) ( Fig. 3 ) and evaluating them for anti-picornavirus activity. The antiviral potency of these synthetic compounds was evaluated against human rhinovirus (HRV) 1B and 14 and poliovirus (PV) 2 by a plaque reduction assay in He La cell cultures. (dd, 1H, H 5 , J 5-6 7.8 Hz,J5-7 1.7 Hz); 7.60-7.48 (m, 1H, H 7 , J 6-7 7.2 Hz, J 7-a 8.4 Hz,J5-7 1.7 Hz); 7.17-6.93 (m, 4H, H 2 " H 6 " H 6 , H a ); 6.80 (d, 2H, H 3 " H 5 " J 2'.3' 8.5 Hz); 4,43 (dd, 1H, H 2 , J gern 11.5 Hz, J 2-3 4.6 Hz); 4.21 (dd, 1H, H 2 , J gern 11.5 Hz, J 2-3 9.1 Hz); 3.16 (dd, 1H, H 9 , J gern 13.7 Hz,J 3-9 4.6 Hz); 3.05-2.83 (m, 1H, H 3 ); 2.05 (dd, 1H, H 9 , J gern 13.7 Hz, J 3-9 9.6 Hz). (CDCI 3 ): 7.92 (dd, 1H, H 5 , J5-6 7.8 Hz,J5-7 1.7 Hz); 7. 52-7.42 (m, 1H, H 7 , J6-7 7.3 Hz, J 7a 8.3 Hz); 7.16 (d, 2H, H 2 " H 6 " J 2 '.3' 8.5 Hz); 7.07-6.91 (m, 2H, H 6 , H a ); 6.86 (d, 2H, H 3 " H 5 " J 2"3' 8.5 Hz); 4.37 (dd, 1H, H 2 , J gern 11.5 Hz,J 2-3 4.3 Hz); 4.17 (dd, 1H, H 2 , J gern 11.5 Hz,J 2-3 7.9 Hz); 3.79 (5, 3H, OCH 3 ); 3.20 (dd, 1H, H 9 , J gern 13.6 Hz,J 3-9 4.2 Hz); 2.96-2.78 (m, 1H, H 3 ); 2.68 (dd, 1H, H 9 , J gern 13.6 Hz, J 3 -9 10.2 Hz).
(CDCI 3 ) : 7.91 (dd, 1H, H 5 , J 5-6 7.9 Hz,J5-7 1.8 Hz); 7.55-7.43 (m, 1H, H 7 , J6-7 7.2 Hz,J 7-a 8.4 Hz); 7.29 (d, 2H, H 2 " H 6 " J 2'.3' 8.4 Hz); 7.17 (d, 2H, H 3 " H 5 " J 2'-3' 8.4 Hz); 7.09-6.92 (m, 2H, H 6 , H a ); 4.37 (dd, 1H, H 2 , J gern 11.5 Hz, J 2-3 4.3 Hz); 4.15 (dd, 1H, H 2 , J gern 11.5 Hz,J 2-3 8.1 Hz); 3.23 (dd, 1H, H 9 , J gern 13.5 Hz, J 3-9 4.3 Hz); 2.98-2.81 (m, 1H, H 3 ); 2.71 (dd, 1H, H 9 , J gern 13.5 Hz, J 3-9 9.9 Hz). (CDCI 3 ): 7.86 (d, 1H, H 5 , J5-7 2.7 Hz); 7.40 (dd, 1H, H 7 , J5-7 2.7 Hz, J 7-a 8.8 Hz); 7.28 (d, 2H, H 2 " H 6 " J 2 " 3' 8.5 Hz); 7.14 (d, 2H, H 3 " H 5 " J 2 '.3' 8.5 Hz); 4.37 (dd, 1H, H 2 , J gern 11.6 Hz,J 2-3 4.4 Hz); 4.24 (dd, 1H, H 2 , J gern 11.6 Hz,J 2-3 4.4 Hz); 3.22 (dd, 1H, H 9 , J gern 13.7 Hz, J 3-9 9.6 Hz); 2.97-2.81 (m, 1H, H 3 ); 2.70 (dd, 1H, H 9 , J gern 13.7 Hz,J 3 -9 9.6 Hz). (CDCI 3 ): 7.29 (d, 2H, H 2 " H 6 " J 2 " 3' 8.5 Hz); 7.15 (d, 2H, H 3 " H 5 " J 2 '.3' 8.5 Hz); 7.06 (d, 1H, H 6 , J6-a 2.0 Hz); 6.92 (d, 1H, H a , J6-a 2.0 Hz); 4.37 (dd, 1H, H 2 , J ern 11.6 Hz, J 2-3 4.5 Hz); 4.15 (dd, 1H, H 2 , J gern 11.6 Hz, J 2-3 8.7 Hz); 3.24 (dd, 1~, H 9 , J gern 13.8 Hz,J 3-9 4.6 Hz); 3.00-2.84 (m, 1H, H 3 ); 2.65 (dd, 1H, H 9 , J gern 13.8 Hz, J 3 -9 9.8 Hz). (CDCI 3 ): 7.16 (d, 2H, H 2 " H 6 " J 2 " 3' 8.5 Hz); 6.86 (d, 2H, H 3 " H 5 " J 2 "3' 8.5 Hz); 6.10-6.02 (m, 2H, H 6 , H a , J6-a 2.3 Hz); 6.06 (d, 1H, H a , J6-a 2.3 Hz); 4.27 (dd, 1H, H 2 , J gern 11.5 Hz, J 2-3 3.9 Hz); 4.08 (dd, 1H, H 2 , J gern 11.5 Hz, J 2-3 7.0Hz); 3.89 (5, 3H, OCH 3 ); 3.82 (5, 3H, OCH 3 ); 3.80 (5, 3H, OCH 3 ); 3.20 (dd, 1H, H 9 , J garn 12.4 Hz, J 3-9 3.7 Hz); 2.81-2.55 (m, 2H, H 3 , H 9 ).
Materials and Experimental Procedures: Chemistry
Melting points were determined on a Buchi SMP-390 apparatus and are uncorrected. All compounds were routinely checked by thin-layer chromatography (TLC) and IH NMR. TLC was performed using 0.25 mm silica gel or aluminium oxide fluorescent coated plates (Kieselgel or aluminium oxide 60 F254; Merck). Compounds were visualized by UV light. Column chromatography was performed using silica gel (0.05-0.20 mm; Carlo Erba) or aluminium oxide (70-230 mesh; Merck). Elemental 548 analyses of the new compounds were performed by the Microanalytical Laboratory (University of Padova, Italy) and were within ±0,4% of theoretical values. Syntheses of (E)-3-benzylidenechroman-4-ones la-d and 19, 3benzyl-4-chromones 2a-d and 2g and 3-benzylchroman-4-ones 3a, 3c, 3d and 3g have been reported previously (Al Nakib et al., 1990; Bohler & Tamm, 1967; Chatterjea et al., 1974; Farkas et al., 1971; Kirkiacharian & Aloulou, 1984; Levai & Schag, 1979; Mulvagh et al, 1979; Pfeiffer et al., 1949) . IH NMR spectra were detected with a Varian EM-390 or a Bruker M200 instrument using Me 4Si as the internal standard. IR 
(£)-3-benzylidenechroman-4-ones (1a-d)
A mixture of chroman-4-one (0.01 mol), substituted benzaldehyde (0.01 mol) and 85% phosphoric acid (20.0 mL) was heated at 80°C for 6 h. After cooling the mixture was diluted with water and the precipitate was filtered off, washed with water and chromatographed (Ia, Ic) or crystallized (Ib, ld). Physicaland chemical data are reported in Tables 1 and 4.
(£)-3-benzylidenechroman-4-ones (1e, 1f)
A mixture of substituted chroman-4-one (Canalini et al., 1967; Merchant & Upasani, 1980 ) (0.01 mol) and 4chlorobenzaldehyde (0.011 mol) in dry ethanol saturated with hydrochloric acid (40.0 mL) was stirred at room temperature for 24 h. The mixture was diluted with ice-water and the precipitate was filtered off, washed with water and chromatographed (Ie) or crystallized (If). Physical and chemical data are reported in Tables 1 and 4. 
3-Benzyl-4-chromones (2a-g)
To a solution of (E)-3-benzylidenechroman-4-ones (1 a-g) (0.01 mol) in chloroform (24 mL for la-e, 19 and 70 mL for If) and ethanol (24 mL for la-e, 19 and 70 mL for If), RhCl 3 (0.5 mmol) and water (1.8 mL for la-e and 5.4 mL for If) were added. The mixture was refluxed under stirring for the time reported in Table 5 . After cooling, the solution was poured into water and extracted with chloroform. The organic layer was dried over Na 2 S0 4 , the solvent was evaporated under reduced pressure and the crude compound was chromatographed (2a-e) or crystallized (2f, 2g). Physical and chemical data are reported in Tables 2 and 5 .
3-Benzylchroman-4-ones (3a-g)
A solution of (E)-3-benzylidenechroman-4-ones (la-g) (0.001 mol) in ethyl acetate (33 mL for la-d, 19) or THF (36 mL for Ie, 14 mL for If) was hydrogenated at room temperature over 10% PdlC (170 rng), until absorption of the theoretical hydrogen amount. After filtration of the catalyst and evaporation of the solvent, the residue was chromatographed (3a-d) or crystallized (3e-g). Physical and chemical data are reported in Tables 3 and 6.
Materials and Experimental Procedures: Virology
Cells HeLa (Ohio) cellswere routinely grown at 37°C in 72 cm 2 tissue culture flasks using Eagle's MEM supplemented with 100 !!g mL-l of streptomycin and 100 U mL-l of penicillin G. Eight percent heat-inactivated fetal calf serum (FCS) was added for cell growth (growth medium); the concentration was reduced to 2% for cell maintenance (maintenance medium).
Compounds
Compounds were initially dissolved in ethanol (lor 0.1 mg ml.:") and further diluted in tissue culture medium shortly before use.
Virus
HRV-1B and -14, and PV-2 (P712) were grown in HeLa (Ohio) cells at 33"C and 37°C, respectively. Virus stocks were prepared by inoculating cell monolayers at low m.o.i. When the CPE involved most of the cell monolayer, the cultures were freeze-thawed three times and the clarified supernatants titrated by plaque assay, essentially as described by Fiala & Kenny (1966) . The virus was stored in aliquots at -80°C until use.
Compound cytotoxicity
Exponentially growing HeLa cells in 24-well plates were cultured for 3 days at 37C in growth medium in the presence or absence of the two-fold serially diluted compounds to be tested.Three wellswere utilized for each drug concentration. On the third day of incubation, treated and mocktreated cells were trypsinized and counted in a haemocytometer and the viabilityof cellswas checked by the trypan blue exclusion method. Cytotoxicity was also scored microscopically as morphological alterations (i.e, swelling, granularity, rounding up, shrinking and detachment). In antiviral tests, compounds were utilized starting from the highest concentration which did not produce any modification of morphology and viability in 100% of the cells in all the wells examined (maximum non-toxic concentration).
Determination of the 50% inhibitory concentration (lCsoJ
The IC so was determined as described previously . Briefly, confluent monolayers of HeLa cells in 6-well plates were infected with a virus suspension producing approximately 100 plaques well-I. After 1 h of incubation at 37°C (PV) or 33°C (HRV), the virus suspension was removed and the cells were overlaid with medium for plaques, in the presence or absence of fourfold dilutions of drugs. After 2 days of incubation at 37C (PV) or 3 days at 33°C (HRV), the cellswere stained with a neutral red solu-Antiviral Chemistry & Chemotherapy 8(6) Anti-picornavirus activity ofhomo-isoAavanoids tion at 0.2 mg mL-l in PBS pH 7.4 and the plaques were counted. The IC so was expressed as the concentration of drug reducing the plaque number by 50% as compared to mock-treated controls. It was calculated from l a dose-response line obtained by plotting the percentage of plaque reduction, with respect to the control plaque count, versus the loglo of compound dose. Triplicate wells were utilized for each drug concentration tested.
Results
Chemistry (E)-3-Benzylidenechroman-4-ones (la-g), 3-benzyl-4chromones (2a-g) and 3-benzylchroman-4-ones (3a-g) utilized in the present study were prepared using previously described methods. In general, (E)-3-benzylidenechroman-4-ones were obtained either by acid-or base-catalysed condensation of chroman-4-ones with aromatic aldehydes (Blasko & Cordell 1988; Chatterjea et al., 1979; Levai et al., 1981; Levai & Szabo, 1992; Namikoshi et al., 1987) . We easily prepared (E)-3-benzylidenechroman-4-ones (la-d) using a phosphoric acid catalyst; however, this method could not be conveniently used for the synthesis of polychloro derivatives (Ie, If) and for (E)-5,7-dimethoxy-3-(4-methoxybenzylidene)chroman-4-one (lg). Therefore these latter compounds were obtained using concentrated or dry hydrogen chloride in ethyl alcohol (Fig. 3) . The lH NMR spectra show that only the (E)-isomer was obtained in each case. Owing to the anisotropic effect of the carbonyl group, the vinyl C-9 proton appears downfield near 7.8 p.p.m., whereas for the (Z)-isomer this signal would appear around 6.9 p.p.m. Also, the C-2 protons of the (Z)-isomer would be shielded with respect to those of the trans-isomer, owing to the greater distance from the side-chain phenyl group.
The synthesis of 3-benzyl-4-chromones (2a-g) was achieved by exocyclic-endocyclic migration of the double bond of (E)-3-benzylidenechroman-4-ones (la-g) using rhodium trichloride as a catalyst (Andrieux et al., 1977) (Fig. 3) . The products of isomerization were identified by their IR and lH NMR spectra. The characteristic C=O band appeared between 1665 and 1650 ern"! for (E)-3benzylidenechroman-4-ones (la-g) and between 1640 and 1630 em? for 3-benzyl-4-chromones (2a-g). lH NMR data showed the upfield shift the of CH 2 signal of 3-benzyl-4-chromones (2a-g) if compared to that of isomers la-g and the disappearance of the allyl coupling (J 1.5-1.9 Hz) between CH 2 and vinyl protons.
Reduction of the exocyclic double bond was obtained by hydrogenation at room temperature using palladium as the catalyst, until absorption of the theoretical hydrogen amount, to avoid the reduction of carbonyl group (Fig. 3 ) (Chatterjea et al., 1979) . The endo isomer was observed as Table 7 . Cytotoxicity and anti-picornavirus activity of 3-benzylidenechroman-4-ones (1 a-g), 3-benzyl-4-chromones (2a-g) and 3-benzylchroman-4-ones (3a-g a byproduct of the reaction.
Antiviral activity
In the first set of experiments, the maximum non-toxic concentration of compounds, in 100% of the cells, was determined. Serial twofold dilutions of compounds in growth medium were applied to HeLa cells and, after 3 days of incubation at 37°C, cell morphology and growth were examined. Data are reported in Table 7 . In general, (E)-3-benzylidenechroman-4-ones (la-g) appeared more toxic than 3-benzyl-4-chromones (2a-g), while the results for 3-benzylchroman-4-ones (3a-g) were found to be variable. For compounds 3a and 3d, the maximum nontoxic concentration was found to be higher than the saturation concentration in cell culture medium (50 I-tM). The antiviral potency of (E)-3-benzylidenechroman-4bnes (la-g), 3-benzyl-4-chromones (2a-g) and 3benzylchroman-4-ones (3a-g) was evaluated in Hel.a cell cultures infected with HRV-lB and -14 and PV-2, selected as representative members of the rhinovirus and 552 enterovirus genera. 4',6-Dichloroflavan (BW683C) (Bauer et al., 1981) was included as a control. The inhibitory effect of homo-isoflavonoids on virus replication was monitored by the reduction of plaque number and size. The 50% effective concentrations on plaque formation (IC so )' obtained from dose-response plots, are shown in Table 7 . When the IC so value was higher than the maximum non-toxic concentration, the percentage inhibition obtained at this dose is reported in parentheses.
Compounds 2c, 2f, 2g, 3e and 3g caused a reduction (about 50%) in viral plaque size ofHRV-lB at the highest dose tested, in addition to an effect on plaque number, suggesting a slowing down in the kinetics of viral replication; none of the other compounds altered the mean viral plaque size.
Substituted homo-isoflavonoids were generally poorly active towards PV-2 infection and the few active analogues reduced the viral plaque number by 50% only at very high doses.(E)-5, 7-dimethoxy-3-(4-methoxybenzylidene) chroman-4-one (lg) was the most effective compound against this virus even though its therapeutic index was very low.
The rhinovirus serotypes tested exhibited a different sensitivity to the compounds. HRV-lB, belonging to the minor group of rhinoviruses according to membrane receptor recognition, was much more susceptible than HRV-14, a representative of the major group. With the exception of 3-(4-hydroxybenzyl)-4-chromone (2b), which was effective at high concentration on HRV-14 only, all the homo-isoflavonoids active on HRV-14 (2a, 2c, 2£, 3d-f) were also effective against HRV-1B and not vice versa.
Among the (E)-3-benzylidenechroman-4-ones synthesized, the chloro-substituted compounds (ld-f) were highly active only against HRV-1B infection, while all the 3-benzyl-4-chromones tested were efficacious towards serotype 1B, with the exception of 3-(4-hydroxybenzyl)-4-chromone (2b). 3-(4-Chlorobenzyl)-4-chromone (2d) was the most effective analogue in this study towards HRV-lB, with an IC so of 0.20~and a high therapeutic index.
Also, the majority of 3-benzylchroman-4-ones interfered with HRV-lB infection of He La cells (3a, 3c-f) and chlorinated compounds (3c-f) exhibited the highest potency. The activity of chloro-substituted compounds of this series extended to all viruses tested.
Owing to the correlation between anti-HRV-1B activity and the presence of chlorine substituents, it was interesting to evaluate the effects of the addition of further chloro atoms on 4'-chloro-homo-isoflavonoids (Id, 2d and 3d). Polychloro substituted 3-benzylidenechroman-4ones (Ie and If) resulted in more potent inhibitors than 3-(4-chlorobenzylidene)chroman-4-one (ld). In contrast, the introduction of a chlorine in the 6 position or of two chlorine atoms in the 5 and 7 positions on 2d or 3d led to a progressive reduction of activity. For 2£ the lower effect against HRV-lB was accompanied by an inhibitory activity towards the other virus tested.
Discussion
In this study we described the synthesis and anti-picornavirus activity of three related classes of homoisoflavonoids (la-g, 2a-g and 3a-g). Besides a well documented effect on several biological activities (Ravise & Kirkiacharian, 1978; Darmanaden et al., 1984; Della Loggia et al., 1989; Kirkiach~rian et al., 1989; Wall et al., 1989; Al Nakib et al., 1990; Amschler et al., 1996) , to our knowledge, this is the first report describing the antiviral properties of this group of compounds. Therefore the homo-isoflavonoids can be considered another class of anti-picornavirus flavonoids along with flavans, flavones, isoflavones, isoflavans, calchones, etc.
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Anti-picornavirus activity of homo-isaflavanoids Horno-isoflavonoids were more effective against HRV than PV. Among HRVs, serotype 1B was more sensitive than serotype 14. Only 3-(4-hydroxybenzyl)-4-chromone (2b) exhibited a higher activity against HRV J14.
Considerable differences were frequently noted in the sensitivity of different HRV serotypes to each compound tested. Flavonoids were generally more effective against serotype 1B (Batchelor et al., 1979; Fujui et al, 1980) . Most of the homo-isoflavonoids tested showed an anti-HRV activity comparable with that of flavonoids previously studied by us (Burali et al., 1987; Conti et al., 1990a; Desideri et al., 1990 Desideri et al., , 1992 Desideri et al., , 1995 .
The replication ofPV-2 was usually weakly sensitive to homo-isoflavonoids. Only compound 19 showed a higher anti-PV activity. It is interesting to note that PV-2 and other enteroviruses were also generally less susceptible than HRV-1B to the action of substituted flavans, isoflavans and isoflavenes, previously synthesized by us (Burali et al., 1987; Conti et al., 1990a,b; Desideri et al., 1990; Genovese et al., 1995) . The different sensitivity of rhinoviruses and enteroviruses to our compounds is not surprising. The structure of rhinoviruses is known to be slightly different from that of enteroviruses (Lonberg-Holm & Butterworth, 1976; Newman et al., 1973) . Our compounds may recognize differences in the fine structure or mechanism of replication among picornaviruses.
Some of the synthesized homo-isoflavonoids (2£, 3d-f) showed a spectrum of action wider than that of the reference drug (BW683C). Interestingly, all these compounds contain at least one chlorine atom, confirming the positive influence of this substituent on anti-picornavirus activity (Burali et al., 1987; Conti et al., 1990a; Desideri et al., 1990 Desideri et al., ,1992 Desideri et al., ,1995 Genovese et al., 1995) .
Further evaluations should be carried out to define more accurately the structure-activity relationships and the mechanism of action towards picornaviruses.
